Vaxart Inc
NASDAQ:VXRT 11:28:43 AM EDT
| Market Cap (Intraday) | 275.20M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.33 |
| 50-Day MA | $3.35 |
| 200-Day MA | $4.30 |
Vaxart Inc Stock, NASDAQ:VXRT
170 Harbor Way, Suite 300, South San Francisco, California 94080
United States of America
Phone: +1.650.550.3500
Number of Employees: 125
Description
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.